Nippon Shinyaku Establishes a Local Subsidiary in China
November 03, 2021
Share
NEWS RELEASE
November 4, 2021
Nippon Shinyaku Establishes a Local Subsidiary in China
Kyoto, Japan, November 4, 2021 - Nippon Shinyaku Co., LTD. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced today that it has established a local subsidiary "Beijing Nippon Shinyaku Co., Ltd." ("Beijing NS") in Beijing as a development and commercial-consulting foothold in China.
Nippon Shinyaku established Beijing Representative Office in December 2011. It has been contributing to the healthcare in China by enhancing cooperation with our import agents, collecting local pharmaceutical information, and providing medical information on our pharmaceutical products. In addition, it has been supporting clinical development of our pharmaceutical products in China.
Beijing NS will assume and further strengthen current activities of Beijing Representative Office, and start working to serve as a local agent of MAH (Marketing Authorization Holder)*.
Nippon Shinyaku has been actively working with a sense of mission to develop pharmaceutical products for the treatment of intractable and rare diseases, and aiming to provide Chinese patients with products such as viltolarsen for Duchenne muscular dystrophy, which we submitted its New Drug Application in China in June 2021.
*local agent of MAH: Where the MAH is an overseas enterprise, an enterprise legal person within the territory of the People's Republic of China shall be designated to fulfill the obligations of the MAH and assume joint liability with the MAH. (Article 38, Drug Administration Law of the People's Republic of China).
Nippon Shinyaku Co. Ltd. published this content on 04 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 November 2021 12:37:10 UTC.
Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.